BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

GSK hay fever drug relieves symptoms
A GlaxoSmithKline allergy medicine currently under review by the FDA, was effective and well-tolerated in treating a range of nasal allergy symptoms such as congestion, sneezing, itchy and runny nose, according to phase III clinical studies.
In two separate phase III studies, fluticasone furoate nasal spray (FFNS) was more effective than placebo in relieving both the nasal and eye symptoms of patients 12 years and older with seasonal allergic rhinitis, commonly known as hay fever.

One additional phase III study among individuals with perennial allergic rhinitis (year-round nasal allergies) found FFNS to be more effective than placebo in relieving nasal symptoms. Moreover, the symptom-relief lasted 24 hours in all three studies.

"These are the first two prospectively-designed phase III studies to demonstrate consistent and significant improvement in eye-related allergy symptoms with an intranasal steroid," commented lead investigator William Lumry, Asthma & Allergy Specialists, Dallas.

 

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.